Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Timothy Wilson

Geriatric Medicine Kansas City, MO Medical Doctor

NPI 1619173549 CMS profile 380640

8930 Evanston Ave, Kansas City, MO 64138

Open in the dashboard

General payments

$1,026

45 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Wilson of Kansas City, MO is reported in the CMS Open Payments database as having received $1,026 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $276 13
2024 General $211 11
2023 General $274 12
2022 General $121 7
2021 General $21 1
2020 General $123 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Wilson
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Timothy Wilson were reported at $276. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Timothy Wilson Geriatric Medicine median Middle half National median
2019 $0 $96 $28–$339 $163
2020 $123 $99 $28–$262 $114
2021 $21 $94 $27–$318 $132
2022 $121 $103 $34–$338 $149
2023 $274 $109 $39–$320 $160
2024 $211 $125 $36–$371 $164
2025 $276 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Teva Pharmaceuticals USA, Inc. $219 11 payments
  2. ITI, Inc. $163 6 payments
  3. Alkermes, Inc. $125 6 payments
  4. Allergan Inc. $123 1 payment
  5. Otsuka America Pharmaceutical, Inc. $96 5 payments
  6. Janssen Pharmaceuticals, Inc $95 6 payments
  7. Neurocrine Biosciences, Inc. $67 3 payments
  8. Indivior Inc. $66 4 payments
  9. AbbVie, Inc. $31 1 payment
  10. Lundbeck LLC $21 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,026 45 payments
Products named General payments · program years 2020–2025
  1. BOTOX $123 1 payment
  2. CAPLYTA $116 4 payments
  3. Austedo XR $92 4 payments
  4. UZEDY $70 4 payments
  5. LYBALVI $68 3 payments
  6. INGREZZA $67 3 payments
  7. PERSERIS $66 4 payments
  8. INVEGA SUSTENNA $62 4 payments
  9. REXULTI $58 3 payments
  10. VIVITROL $58 3 payments
  11. Other $564 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

872

Median for Family Practice: 1,826

Drug cost

$49,009

Median for Family Practice: $120,094

Branded share of claims

14.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $17,426
Januvia Sitagliptin Phosphate Brand 12 $8,965
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,261
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $3,079
Promethazine Hcl Generic 37 $1,949
Oxycodone Hcl Generic 67 $1,894
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $1,604
Potassium Chloride Generic 45 $1,347
Gabapentin Generic 51 $1,338
Methenamine Hippurate Generic 12 $1,278

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $48
$48 — —
PERSERIS
  • Indivior Inc. $32
$32 — —
LYBALVI
  • Alkermes, Inc. $25
$25 — —
VIVITROL
  • Alkermes, Inc. $23
$23 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record